JP Morgan Maintains Overweight on Revolution Medicines, Lowers Price Target to $54
Portfolio Pulse from Benzinga Newsdesk
JP Morgan analyst Eric Joseph maintains an Overweight rating on Revolution Medicines (NASDAQ:RVMD) but lowers the price target from $55 to $54.

August 08, 2024 | 4:25 pm
News sentiment analysis
Sort by:
Descending
NEUTRAL IMPACT
JP Morgan analyst Eric Joseph maintains an Overweight rating on Revolution Medicines but lowers the price target from $55 to $54.
The Overweight rating suggests a positive outlook, but the slight reduction in the price target indicates a minor adjustment in expectations. This mixed signal is likely to result in a neutral short-term impact on the stock price.
CONFIDENCE 90
IMPORTANCE 70
RELEVANCE 100